(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of 4.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Arbutus Biopharma's revenue in 2025 is $6,403,000.On average, 2 Wall Street analysts forecast ABUS's revenue for 2025 to be $1,120,433,705, with the lowest ABUS revenue forecast at $881,024,793, and the highest ABUS revenue forecast at $1,359,842,616. On average, 1 Wall Street analysts forecast ABUS's revenue for 2026 to be $651,192,239, with the lowest ABUS revenue forecast at $651,192,239, and the highest ABUS revenue forecast at $651,192,239.
In 2027, ABUS is forecast to generate $1,691,184,549 in revenue, with the lowest revenue forecast at $1,691,184,549 and the highest revenue forecast at $1,691,184,549.